



# State of Louisiana

Louisiana Department of Health  
Bureau of Health Services Financing

## PRIOR AUTHORIZATION REQUEST COVERSHEET

Please check the member's appropriate health plan listed below:

<input type="checkbox"/> <b>Aetna Better Health of Louisiana</b>	Retail Pharmacy Requests <b>Phone:</b> 1-855-242-0802 <b>Fax:</b> 1-844-699-2889	Medical Benefit – Physician Administered Drugs <b>Phone:</b> 1-855-242-0802 <b>Fax:</b> 1-844-227-9205
<input type="checkbox"/> <b>AmeriHealth Caritas Louisiana</b>	Retail Pharmacy and Provider-Administered Drug Requests <b>Phone:</b> 1-800-684-5502 <b>Fax:</b> 1-855-452-9131	
<input type="checkbox"/> <b>Fee-for-Service (FFS) Louisiana Legacy Medicaid</b>	Retail Pharmacy Requests <b>Phone:</b> 1-866-730-4357 <b>Fax:</b> 1-866-797-2329	
<input type="checkbox"/> <b>Healthy Blue</b>	Retail Pharmacy Requests <b>Phone:</b> 1-844-521-6942 <b>Fax:</b> 1-855-592-0978	Medical Benefit – Physician Administered Drugs <b>Phone:</b> 1-844-521-6942 <b>Fax:</b> 1-844-487-9291
<input type="checkbox"/> <b>Humana</b>	Retail Pharmacy Requests <b>Phone:</b> 1-800-555-2546 <b>Fax:</b> 1-877-486-2621	Professionally Administered Drugs <b>Phone:</b> 1-866-461-7273 (M–F, 7am-10pm CT) <b>Fax:</b> 1-888-447-3430
<input type="checkbox"/> <b>LA Healthcare Connections</b>	Retail Pharmacy Requests <b>Phone:</b> 1-866-595-8133 <b>Fax:</b> 1-833-645-2733	Physician Administered Medication (Buy and Bill) <b>Phone:</b> 1-866-595-8133 <b>Fax:</b> 1-866-925-3006
<input type="checkbox"/> <b>UnitedHealthcare</b>	Retail Pharmacy Requests <b>Phone:</b> 1-800-310-6826 <b>Fax:</b> 1-866-940-7328	Medical Injectables <b>Phone:</b> 1-888-397-8129

### PRIVACY AND CONFIDENTIALITY WARNING

*This facsimile transmission may contain Protected Health Information, Individual Identifiable Health Information and other information which is protected by law. The information is intended only for the use of the intended recipient. If you are not the intended recipient, you are hereby notified that any review, disclosure/re-disclosure, copying, storing, distributing or the taking of action in reliance on the content of this facsimile transmission and any attachments thereto, is strictly prohibited. If you have received this facsimile transmission in error, please notify the sender immediately via telephone and destroy the contents of this facsimile transmission and its attachments.*

PLEASE CALL IF YOU HAVE ANY PROBLEMS RECEIVING THIS FAX OR IF PAGES ARE MISSING

**Louisiana Medicaid**  
**Palivizumab Clinical Authorization Form**

Palivizumab Form: Rx PA01P  
Effective Date: 10/01/2025

Requests utilizing this form must be faxed. Please type or print legibly. Incomplete forms will not be approved.  
Requests submitted via electronic PA (ePA) must include all required information and supporting documentation.

Date of Request \_\_\_\_\_

Prescribing Provider Information		Recipient Information	
Name (Last, First)		Name (Last, First)	
LA Medicaid Prescribing Provider Number / NPI		LA Medicaid CCN or Recipient Number	
Call-Back Phone Number (include area code)	Date of Birth (mm/dd/yy)	Gestational Age (weeks/days)	
FAX Number (include area code)	Recipient Current Weight _____ kg as of _____ (mm/dd/yy)		
Drug and Strength Requested	Diagnosis Code(s) (ICD-10-CM) to Justify Palivizumab Use		
Office Contact Name	EPSDT Support Coordinator (Name / Address) (optional)		

Does the infant have additional insurance coverage (TPL)? \_\_\_ Yes \_\_\_ No If Yes, please contact TPL to determine coverage for this drug.

Is this request for palivizumab dosing in the child's second RSV season? \_\_\_ Yes \_\_\_ No

Does the child have a documented contraindication to nirsevimab that is not also a contraindication to palivizumab? [Supporting documentation must be provided] \_\_\_ Yes \_\_\_ No

Check the applicable high-risk condition that applies to this child. Attach supporting documentation (e.g. hospital birth discharge notes and/or chart notes) for any submitted qualifying criteria or ICD-10 diagnosis code(s).

☐ The child is in their second RSV season and is at least 8 months of age but is less than 20 months of age on November 1.

☐ Child with CLD of prematurity, defined as an infant with gestational age of less than 32 weeks, 0 days who required supplemental oxygen greater than 21% for at least the first 28 days after birth **AND** child continued to require medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) at any time during the 6-month period before the start of the infant's second respiratory syncytial virus (RSV) season, which is November 1.

☐ Child will be profoundly immunocompromised during RSV season (November 1 through March 31) due to \_\_\_\_\_

☐ Child has cystic fibrosis with **ONE** of the following:

- ☐ Manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable), **OR**
- ☐ Weight-for-length that is less than the 10<sup>th</sup> percentile.

☐ Child is American Indian or Alaska Native.

Has the infant received a dose of nirsevimab (Beyfortus™) for the current RSV season? \_\_\_\_ Yes \_\_\_\_ No

Pharmacy Information (Optional) Pharmacy Name \_\_\_\_\_ Phone \_\_\_\_\_

Prescribing Physician Signature:\* \_\_\_\_\_ Date: \_\_\_\_\_

\*(Signature stamps and proxy signatures are not acceptable)

**CONFIDENTIAL NOTICE**

The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity to which it is addressed. If you are not the intended recipient you are hereby notified that any review, disclosure/re-disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy this information.